Effectiveness of BNT162b2 (Pfizer-BioNTech) mRNA Vaccination Against Multisystem Inflammatory Syndrome in Children Among Persons Aged 12–18 Years — U.S. July–December 2021

Details

• Journal Article:
  Morbidity and Mortality Weekly Report (MMWR)
• Personal Author:
  Zambrano, Laura D. ; Newhams, Margaret M. ; Olson, Samantha M. ; Halasa, Natasha B. ; Price, Ashley M. ; Boom, Julie A. ; Sahni, Leila C. ; Kamidani, Satoshi ; Tarquinio, Keiko M. ; Maddux, Aline B. ; Heidemann, Sabrina M. ; Bhumbra, Samina S. ; Bline, Katherine E. ; Nofziger, Ryan A. ; Hobbs, Charlotte V. ; Bradford, Tamara T. ; Cvijanovich, Natalie Z. ; Irby, Katherine ; Mack, Elizabeth H. ; Cullimore, Melissa L. ; Pannaraj, Pia S. ; Kong, Michele ; Walker, Tracie C. ; Gertz, Shira J. ; Michelson, Kelly N. ; Cameron, Melissa A. ; Chiotos, Kathleen ; Maamari, Mia ; Schuster, Jennifer E. ; Orzel, Amber O. ; Patel, Manish M. ; Campbell, Angela P. ; Randolph, Adrienne G. ; Murdock, Meghan ; Gaspers, Mary Glas ; Typpo, Katri V. ; Kelley, Connor P. ; Sanders, Ronald C. ; Yates, Masson ; Smith, Chelsea ; Crane, Katheryn ; Lionetti, Geraldina ; Murcia-Montoya, Juliana ; Zinter, Matt S. ; Villarreal-Chico, Denise ; Skura, Adam L. ; Peralta, Harvey ; Lockwood, Justin M. ; Port, Emily ; Carson, Imogene A. ; Chatani, Brandon M. ; Hussaini, Laila ; Baida, Nadine ; Coates, Bria M. ; Rowan, Courtney M. ; Stumpf, Mary ; Johnston, Marla S. ; Boutselis, Benjamin J. ; Kucukak, Suden ; Chen, Sabrina R. ; Weller, Edie ; Berbert, Laura ; He, Jie ; Flori, Heidi R. ; Hume, Janet R. ; Bruno, Ellen R. ; Goertzen, Lexie A. ; Levy, Emily R. ; Behl, Supriya ; Drapeau, Noelle M. ; Martin, Lora ; Malloch, Lacy ; Sanders, Cameron ; Patterson, Kayla ; Dhanrajani, Anita ; Hill, Shannon M. ; Kietzman, Abigail ; Rinehart, Valerie H. ; Hoody, Lauren A. ; Schwartz, Stephanie P. ; Navas, Angelo G. ; Bennett, Paris C. ; Twinem, Nicole A. ; Tomcany, Merry L. ; Staat, Mary Allen ; Rohlfs, Chelsea C. ; Wolfe, Amber ; Douglas, Rebecca L. ; Phengchomphet, Kathlyn ; Bickford, Megan M. ; Wakefield, Lauren E. ; Smallcomb, Laura ; Stewart, Laura S. ; Golchha, Meena ; Oates, Jennifer N. ; Bowens, Cindy
• Corporate Authors:
  Overcoming COVID-19 Investigators
• Description:
  Multisystem inflammatory syndrome in children (MIS-C) is a severe postinfectious hyperinflammatory condition, which generally occurs 2-6 weeks after a typically mild or asymptomatic infection with SARS-CoV-2, the Virus that causes COVID-19 (1-3). In the U.S. the BNT162b2 (Pfizer-BioNTech) COVID-19 vaccine is currently authorized for use in children and adolescents aged 5-15 years under an Emergency Use Authorization and is fully licensed by the Food and Drug Administration for persons aged ≥16 years (4). Prelicensure randomized trials in persons aged ≥5 years documented high vaccine efficacy and immunogenicity (5),| and real-world studies in persons aged 12-18 years demonstrated high vaccine effectiveness (VE) against severe COVID-19 (6). Recent evidence suggests that COVID-19 vaccination is associated with lower MIS-C incidence among adolescents (7); however, VE of the 2-dose Pfizer-BioNTech regimen against MIS-C has not been evaluated. The effectiveness of 2 doses of Pfizer-BioNTech vaccine received ≥28 days before hospital admission in preventing MIS-C was assessed using a test-negative case-control design| among hospitalized patients aged 12-18 years at 24 pediatric hospitals in 20 states** during July 1-December 9, 2021, the period when most MIS-C patients could be temporally linked to SARS-CoV-2 B.1.617.2 (Delta) Variants predominance. Patients with MIS-C (case-patients) and two groups of hospitalized controls matched to case-patients were evaluated: test-negative controls had at least one COVID-19-like symptom and negative SARS-CoV-2 reverse transcription-polymerase chain reaction (RT-PCR) or antigen-based assay results, and syndrome-negative controls were hospitalized patients without COVID-19-like illness. Among 102 MIS-C case-patients and 181 hospitalized controls, estimated effectiveness of 2 doses of Pfizer-BioNTech vaccine against MIS-C was 91% (95% CI = 78%-97%). All 38 MIS-C patients requiring life support were unvaccinated. Receipt of 2 doses of the Pfizer-BioNTech vaccine is associated with a high level of protection against MIS-C in persons aged 12-18 years, highlighting the importance of vaccination among all eligible children.
• Subjects:
  Adolescent BNT162 Vaccine Case-Control Studies Child COVID-19 Female Hospitalization Humans Male Patient Acuity SARS-CoV-2 Systemic Inflammatory Response Syndrome Vaccine Efficacy

  More +
• Source:
  MMWR Morbidity Mortal Weekly Rep. 71(2):52-58
• Series:
  Weekly Report: Morbidity and Mortality Weekly Report (MMWR)
• DOI:
  http://dx.doi.org/10.15585/MMWRmm7102e1
• ISSN:
  0149-2195 (print) ; 1545-861X (digital)
• Pubmed ID:
  35025852
• Pubmed Central ID:
  PMC8757620
• Document Type:
  Journal Article
• Place as Subject:
  United States
• Pages in Document:
  7 pdf pages
• Volume:
  71
• Issue:
  2
• Collection(s):
  Morbidity and Mortality Weekly Report (MMWR)
• Main Document Checksum:
  urn:sha-512:b4c47748ea315b896a1b6be0d12da9c869c3b5513ca231b5c0f41e7d202a7624d8384dc01b49c1823b5455f88b0adc39a4cff20c66014d464099dd7b828f773c
• Download URL:
  https://stacks.cdc.gov/view/cdc/114305/cdc_114305_DS1.pdf
• File Type:
  [PDF - 146.84 KB ]